These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37301789)

  • 1. A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States.
    Hernandez I; Divino V; Xie L; Hood DW; DeKoven M; Kariuki W; Bell G; Russ C; Cheng D; Cato M; Atreja N; Hines DM
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):559-572. PubMed ID: 37301789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Charlton A; Vidal X; Sabaté M; Bailarín E; Martínez LML; Ibáñez L
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1210-1220. PubMed ID: 34464214
    [No Abstract]   [Full Text] [Related]  

  • 6. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2020 May; 26(5):639-651. PubMed ID: 32347184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
    Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
    Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
    Lip GYH; Keshishian AV; Kang AL; Dhamane AD; Luo X; Li X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig S
    J Intern Med; 2021 Jan; 289(1):42-52. PubMed ID: 32602228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
    Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
    Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
    Lip GYH; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Deitelzweig S
    JAMA Netw Open; 2021 Aug; 4(8):e2120064. PubMed ID: 34398204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.